FDA Calls for Sweeping Review of Opioids Policies

FDA Calls for Sweeping Review of Opioids Policies

Top officials for the organization have called for an action plan to reassess the agency's approach to opioid medications. FDA also will convene an expert advisory committee before approving any new drug application for an opioid that does not have abuse-deterrent properties.

Dr. Robert Califf, deputy commissioner for Medical Products and Tobacco for the FDA, and other top agency officials have called for an action plan to reassess the agency's approach to opioid medications. The plan will focus on policies aimed at reversing the epidemic while still providing patients access to effective relief.

FDA will also seek outside guidance from experts in pain management and drug abuse.

"We are determined to help defeat this epidemic through a science-based and continuously evolving approach," said Califf. "This plan contains real measures this agency can take to make a difference in the lives of so many people who are struggling under the weight of this terrible crisis."

The agency also is making the requirements for drug companies to generate postmarket data stronger, resulting in more comprehensive data with regards to pain medicine and treatments for opioid use disorder.

"Agencies from across the Department of Health and Human Services and throughout the federal government are united in aggressively addressing this public health crisis," said U.S. Health and Human Services Secretary Sylvia M. Burwell. "The FDA is a vital component to combating this epidemic, and the innovation and modernization they have committed to undertaking is an important part of the overall efforts at HHS."

FDA indicated it will re-examine the risk-benefit paradigm for opioids and ensure that the agency considers their wider public health effects and also will convene an expert advisory committee before approving any new drug application for an opioid that does not have abuse-deterrent properties.

FDA reported it already has asked the National Academies of Sciences, Engineering, and Medicine to help develop a framework for opioid review, approval, and monitoring, a framework that balances individuals' need for pain control with considerations of the broader public health consequences of opioid misuse and abuse.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Complete Online Safety Training Courses

    Deliver state-of-the art, online safety training courses to your organization with IndustrySafe Training Management Software. Generate reports to track training compliance and automatically notify learners of upcoming or overdue classes.

  • Easy to Use Safety Inspection App

    Conduct inspections on the go with IndustrySafe’s mobile app. Complete safety audits at job sites and remote locations—with or without web access.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Analyze Incident Data and Maintain OSHA Compliance

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Industry Safe
comments powered by Disqus